MoonLake Immunotherapeutics Stock Analysis & AI Score
MoonLake Immunotherapeutics (MLTX) has an ST Score of 45.9 (C+), driven by its Sentiment (A+) and held back by its Growth (F). Analysts rate it Buy with a $50.00 price target (+312.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
MoonLake Immunotherapeutics (MLTX) has an ST Score of 45.9 (C+), driven by its Sentiment (A+) and held back by its Growth (F). Analysts rate it Buy with a $50.00 price target (+312.5% upside).
- Strongest
- SentimentA+
- Weakest
- GrowthF
All factor grades
- SentimentA+
- ForecastA
- Financial StrengthB
- ValuationB-
- ProfitabilityC
- MomentumD-
- GrowthF
- Piotroski1/9
Contact
MLTX stock: frequently asked questions
What is MLTX's ST Score?
MoonLake Immunotherapeutics (MLTX) has an ST Score of 45.9 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is MLTX a buy, hold, or sell?
Analysts rate MLTX a Buy, with a price target of $50.00 (+312.5% vs the current price). Our ST Score grades it C+ (45.9/100). The ST Score is a data-driven signal, not a recommendation.
What are MLTX's factor grades?
Valuation B-, Profitability C, Financial Strength B, Momentum D-, Growth F, Forecast A, Sentiment A+.
What is MLTX's valuation grade?
MoonLake Immunotherapeutics (MLTX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is MLTX's growth grade?
MoonLake Immunotherapeutics (MLTX) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is MLTX's profitability grade?
MoonLake Immunotherapeutics (MLTX) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is MLTX's financial strength grade?
MoonLake Immunotherapeutics (MLTX) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for MLTX?
The average analyst price target for MoonLake Immunotherapeutics (MLTX) is $50.00 from 19 analysts, which is +312.5% versus the recent price of $12.12.
What is MLTX's Piotroski score?
MoonLake Immunotherapeutics (MLTX) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.